Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma Read more about Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study Read more about Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases Read more about A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Read more about I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma Read more about A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Read more about Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Read more about Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Surveillance AFter Extremity Tumor surgerY Read more about Surveillance AFter Extremity Tumor surgerY
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1 Read more about An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma Read more about Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma